BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24911380)

  • 21. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
    Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
    Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
    Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
    Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
    Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG
    Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Excretion and biotransformation of ketanserin after oral and intravenous administration in rats and dogs.
    Meuldermans W; Hendrickx J; Lauwers W; Swysen E; Hurkmans R; Knaeps F; Woestenborghs R; Heykants J
    Drug Metab Dispos; 1984; 12(6):772-81. PubMed ID: 6150829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
    Balani SK; Xu X; Pratha V; Koss MA; Amin RD; Dufresne C; Miller RR; Arison BH; Doss GA; Chiba M; Freeman A; Holland SD; Schwartz JI; Lasseter KC; Gertz BJ; Isenberg JI; Rogers JD; Lin JH; Baillie TA
    Drug Metab Dispos; 1997 Nov; 25(11):1282-7. PubMed ID: 9351905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disposition and metabolism of finasteride in dogs.
    Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
    Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway.
    Kassahun K; Black WC; Nicoll-Griffith D; McIntosh I; Chauret N; Day S; Rosenberg E; Koeplinger K
    Drug Metab Dispos; 2011 Jun; 39(6):1079-87. PubMed ID: 21422190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs.
    Zhang D; Raghavan N; Chen SY; Zhang H; Quan M; Lecureux L; Patrone LM; Lam PY; Bonacorsi SJ; Knabb RM; Skiles GL; He K
    Drug Metab Dispos; 2008 Feb; 36(2):303-15. PubMed ID: 17984286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing.
    Clarke SE; Austin NE; Bloomer JC; Haddock RE; Higham FC; Hollis FJ; Nash M; Shardlow PC; Tasker TC; Woods FR
    Xenobiotica; 1994 Nov; 24(11):1119-31. PubMed ID: 7701853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans.
    Atsriku C; Hoffmann M; Ye Y; Kumar G; Surapaneni S
    Xenobiotica; 2015 May; 45(5):428-41. PubMed ID: 25482583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.
    Vermeir M; Naessens I; Remmerie B; Mannens G; Hendrickx J; Sterkens P; Talluri K; Boom S; Eerdekens M; van Osselaer N; Cleton A
    Drug Metab Dispos; 2008 Apr; 36(4):769-79. PubMed ID: 18227146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees.
    Riska PS; Joseph DP; Dinallo RM; Davidson WC; Keirns JJ; Hattox SE
    Drug Metab Dispos; 1999 Dec; 27(12):1434-47. PubMed ID: 10570025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
    Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
    Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism and excretion of 6-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 inhibitor, in rats and dogs and assessment of its metabolic profile in plasma of humans.
    Xu L; Woodward C; Dai J; Prakash C
    Drug Metab Dispos; 2013 Dec; 41(12):2133-47. PubMed ID: 24046333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
    Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
    Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat.
    Matsui K; Mishima M; Nagai Y; Yuzuriha T; Yoshimura T
    Drug Metab Dispos; 1999 Dec; 27(12):1406-14. PubMed ID: 10570021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.
    Prakash C; Cui D; Potchoiba MJ; Butler T
    Drug Metab Dispos; 2007 Aug; 35(8):1350-64. PubMed ID: 17496205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats.
    Forkuo AD; Ansah C; Pearson D; Gertsch W; Cirello A; Amaral A; Spear J; Wright CW; Rynn C
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):84. PubMed ID: 29273084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans.
    Dalvie D; Chen W; Zhang C; Vaz AD; Smolarek TA; Cox LM; Lin J; Obach RS
    Drug Metab Dispos; 2008 Nov; 36(11):2185-98. PubMed ID: 18694908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.